Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Return on Assets (ROA) 
since 2005

Microsoft Excel

Calculation

Abiomed Inc., ROA, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31), 10-K (reporting date: 2016-03-31), 10-K (reporting date: 2015-03-31), 10-K (reporting date: 2014-03-31), 10-K (reporting date: 2013-03-31), 10-K (reporting date: 2012-03-31), 10-K (reporting date: 2011-03-31), 10-K (reporting date: 2010-03-31), 10-K (reporting date: 2009-03-31), 10-K (reporting date: 2008-03-31), 10-K (reporting date: 2007-03-31), 10-K (reporting date: 2006-03-31), 10-K (reporting date: 2005-03-31).

1 US$ in thousands

The financial data reveals several notable patterns over the observed periods. Net income (loss) demonstrates a marked transition from consistent negative values in the early years to sustained positive income from the period ending March 31, 2012, onward. Initially, losses were substantial, peaking at nearly -29,449 thousand US dollars. However, after this period, net income shows increasing profitability, reaching a peak of 259,016 thousand US dollars by March 31, 2019, before experiencing a decline in the subsequent years, though remaining positive.

Total assets exhibit a clear upward trajectory throughout the entire period. Starting at 61,061 thousand US dollars, total assets more than doubled by the year ending March 31, 2010, and continued to expand robustly in the following years. By the last period, total assets stand at 1,673,393 thousand US dollars, signifying substantial growth and expansion of the asset base.

Return on Assets (ROA) reflects the transition in profitability described previously. Early periods are characterized by negative ROA, with the lowest point at -37.5%, corresponding with the highest net losses. After the turnaround in net income, ROA improves significantly, becoming positive in the period ending March 31, 2012. The highest ROA value of 33.6% is observed in the period ending March 31, 2014, indicating effective utilization of assets to generate profits. Although ROA declines somewhat after this peak, it remains positive throughout the latter part of the timeline, demonstrating continued profitability, albeit with some variability.

Overall, the data reflects a company that experienced significant financial difficulties in the early years, as indicated by large net losses and negative returns. The steady growth in total assets suggests ongoing investment and expansion efforts during the entire period. The eventual return to profitability and positive asset returns indicates a successful financial turnaround and improved operational efficiency in more recent years. Nonetheless, the variability in net income and ROA in the later years suggests some ongoing challenges in maintaining consistent growth and profitability.

Net Income (Loss)
Shifted from consistent losses early on to robust profitability from 2012 onwards, peaking in 2019, followed by some decline but remaining positive.
Total Assets
Displayed sustained growth across the entire period, expanding nearly 27-fold from 2005 to 2022, indicating significant asset accumulation and business expansion.
Return on Assets (ROA)
Negative in the early periods, reflecting losses, then turning positive with substantial improvements peaking in 2014, followed by moderate fluctuations but remaining positive.

Comparison to Competitors

Abiomed Inc., ROA, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31), 10-K (reporting date: 2016-03-31), 10-K (reporting date: 2015-03-31), 10-K (reporting date: 2014-03-31), 10-K (reporting date: 2013-03-31), 10-K (reporting date: 2012-03-31), 10-K (reporting date: 2011-03-31), 10-K (reporting date: 2010-03-31), 10-K (reporting date: 2009-03-31), 10-K (reporting date: 2008-03-31), 10-K (reporting date: 2007-03-31), 10-K (reporting date: 2006-03-31), 10-K (reporting date: 2005-03-31).


Comparison to Sector (Health Care Equipment & Services)

Abiomed Inc., ROA, long-term trends, comparison to sector (health care equipment & services)

Microsoft Excel

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31), 10-K (reporting date: 2016-03-31), 10-K (reporting date: 2015-03-31), 10-K (reporting date: 2014-03-31), 10-K (reporting date: 2013-03-31), 10-K (reporting date: 2012-03-31), 10-K (reporting date: 2011-03-31), 10-K (reporting date: 2010-03-31), 10-K (reporting date: 2009-03-31), 10-K (reporting date: 2008-03-31), 10-K (reporting date: 2007-03-31), 10-K (reporting date: 2006-03-31), 10-K (reporting date: 2005-03-31).


Comparison to Industry (Health Care)

Abiomed Inc., ROA, long-term trends, comparison to industry (health care)

Microsoft Excel

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31), 10-K (reporting date: 2016-03-31), 10-K (reporting date: 2015-03-31), 10-K (reporting date: 2014-03-31), 10-K (reporting date: 2013-03-31), 10-K (reporting date: 2012-03-31), 10-K (reporting date: 2011-03-31), 10-K (reporting date: 2010-03-31), 10-K (reporting date: 2009-03-31), 10-K (reporting date: 2008-03-31), 10-K (reporting date: 2007-03-31), 10-K (reporting date: 2006-03-31), 10-K (reporting date: 2005-03-31).